This abstract is part of the Presidential Symposium AN OPEN-LABEL, RANDOMISED, PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX

被引：0

作者：

Dimopoulos, M. A. ^{[1
]}

Oriol, A. ^{[2
]}

Nahi, H. ^{[3
,4
]}

Miguel, J. S. ^{[5
]}

Bahlis, N. J. ^{[6
]}

Rabin, N. ^{[7
]}

Orlowski, R. ^{[8
]}

Komarnicki, M. ^{[9
]}

Suzuki, K. ^{[10
]}

Plesner, T. ^{[11
,12
]}

Samoilova, O. S. ^{[13
]}

Yoon, S. S. ^{[14
]}

Yehuda, D. B. ^{[15
]}

Richardson, P. G. ^{[16
]}

Goldschmidt, H. ^{[17
,18
]}

Reece, D. ^{[19
]}

Khokhar, N. ^{[20
]}

O'Rourke, L. ^{[20
]}

Chiu, C. ^{[20
]}

Qin, X. ^{[21
]}

Guckert, M. ^{[20
]}

Ahmadi, T. ^{[20
]}

Moreau, P. ^{[22
]}

机构：

[1] Univ Athens, Athens, Greece

[2] HGTiP, Inst Catala Oncol, Barcelona, Spain

[3] Karolinska Inst, Stockholm, Sweden

[4] Karolinska Univ Hosp Huddinge, Div Hematol, Dept Med, Stockholm, Sweden

[5] Univ Navarra Clin, CIMA, Pamplona, Spain

[6] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[7] Univ Coll London Hosp NHS Trust, Dept Haematol, London, England

[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[9] Poznan Univ Med Sci, Dept Hematol & Stem Cell Transplantat, Poznan, Poland

[10] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[11] Vejle Hosp, Vejle, Denmark

[12] Univ Southern Denmark, Vejle, Denmark

[13] Nizhny Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia

[14] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[15] Hadassah Hebrew Univ Med Ctr, Hematol Dept, Jerusalem, Israel

[16] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[17] Univ Hosp Heidelberg, Heidelberg, Germany

[18] German Canc Res Ctr, Heidelberg, Germany

[19] Princess Margaret Canc Ctr, CCRU, Toronto, ON, Canada

[20] Janssen Res & Dev, Spring House, PA USA

[21] Janssen Res & Dev, Horsham, PA USA

[22] Univ Hosp Hotel Dieu, Hematol, Nantes, France

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LB2238

引用

页码：342 / 342

页数：1

共 50 条

[1] UPDATED EFFICACY AND SAFETY ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRd) VERSUS LENALIDOMIDE AND DEXAMETHASONE (Rd) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM; POLLUX)
Moreau, P.
White, D.
Benboubker, L.
Cook, G.
Leiba, M.
Morton, J.
Ho, P. J.
Kim, K.
Takezako, N.
Trivedi, S.
Wu, K.
Casneuf, T.
Chiu, C.
Schecter, J. M.
Dimopoulos, M. A.
HAEMATOLOGICA, 2018, 103 : 31 - 31
[2] Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux
Dimopoulos, Meletios A.
White, Darrell J.
Benboubker, Lofti
Cook, Gordon
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Trivedi, Sonali
Wu, Kaida
Casneuf, Tineke
Chiu, Christopher
Schecter, Jordan
Moreau, Philippe
BLOOD, 2017, 130
[3] Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).
Bahlis, Nizar J.
Moreau, Philippe
Nahi, Hareth
Plesner, Torben
Goldschmidt, Hartmut
Suzuki, Kenshi
Orlowski, Robert Z.
Rabin, Neil
Leiba, Merav
Oriol, Albert
Chari, Ajai
Miguel, Jesus San
Richardson, Paul G.
Usmani, Saad Zafar
O'Rourke, Lisa Marie
Wu, Kaida
Casneuf, Tineke
Chiu, Christopher
Qin, Xiang
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
Dimopoulos, Meletios A.
San-Miguel, Jesus
Belch, Andrew
White, Darrell
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Kaufman, Jonathan L.
Sutherland, Heather J.
Lalancette, Marc
Magen, Hila
Iida, Shinsuke
Kim, Jin Seok
Prince, H. Miles
Cochrane, Tara
Oriol, Albert
Bahlis, Nizar J.
Chari, Ajai
O'Rourke, Lisa
Wu, Kaida
Schecter, Jordan M.
Casneuf, Tineke
Chiu, Christopher
Soong, David
Sasser, A. Kate
Khokhar, Nushmia Z.
Avet-Loiseau, Herve
Usmani, Saad Z.
HAEMATOLOGICA, 2018, 103 (12) : 2088 - 2096
[5] Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux
Moreau, Philippe
Oriol, Albert
Kaufman, Jonathan L.
Sutherland, Heather
Lalancette, Marc
Magen, Hila
Iida, Shinsuke
Kim, Jin Seok
Prince, Miles
Cochrane, Tara
O'Rourke, Lisa
Wu, Kaida
Schecter, Jordan M.
Bahlis, Nizar J.
BLOOD, 2017, 130
[6] Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)
Bahlis, Nizar
Dimopoulos, Meletios A.
White, Darrell J.
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Krevvata, Maria
Chiu, Christopher
Qin, Xiang
Okonkwo, Linda
Trivedi, Sonali
Qi, Ming
San-Miguel, Jesus F.
BLOOD, 2018, 132
[7] Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)
Kaufman, Jonathan L.
Usmani, Saad Z.
San-Miguel, Jesus
Bahlis, Nizar
White, Darrell J.
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Krevvata, Maria
Pei, Huiling
Ukropec, Jon
Renaud, Thomas
Trivedi, Sonali
Kobos, Rachel
Dimopoulos, Meletios A.
BLOOD, 2019, 134
[8] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Bahlis, Nizar J.
Dimopoulos, Meletios A.
White, Darrell J.
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Kaufman, Jonathan L.
Krevvata, Maria
Chiu, Christopher
Qin, Xiang
Okonkwo, Linda
Trivedi, Sonali
Ukropec, Jon
Qi, Ming
San-Miguel, Jesus
LEUKEMIA, 2020, 34 (07) : 1875 - 1884
[9] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Nizar J. Bahlis
Meletios A. Dimopoulos
Darrell J. White
Lotfi Benboubker
Gordon Cook
Merav Leiba
P. Joy Ho
Kihyun Kim
Naoki Takezako
Philippe Moreau
Jonathan L. Kaufman
Maria Krevvata
Christopher Chiu
Xiang Qin
Linda Okonkwo
Sonali Trivedi
Jon Ukropec
Ming Qi
Jesus San-Miguel
Leukemia, 2020, 34 : 1875 - 1884
[10] EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED ANALYSIS OF POLLUX
Dimopoulos, M. A.
Moreau, P.
Nahi, H.
Plesner, T.
Goldschmidt, H.
Suzuki, K.
Orlowski, R. Z.
Rabin, N.
Leiba, M.
Oriol, A.
Chari, A.
San-Miguel, J.
Richardson, P. G.
Usmani, S. Z.
O'Rourke, L.
Wu, K.
Casneuf, T.
Chiu, C.
Qin, X.
Bahlis, N. J.
HAEMATOLOGICA, 2017, 102 : 108 - 109

← 1 2 3 4 5 →